A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
HonorHealth Research Insisute, Scottsdale, Arizona, United States
Contact: Study coordinator (Justin Moser, MD)UC San Diego Moores Cancer Center, La Jolla, California, United States
Contact: Study coordinator (Gregory Daniels, MD)The Angeles Clinic and Research Institute, Los Angeles, California, United States
Contact: Study coordinator (Inderjit Mehmi, MD)University of California Los Angeles, Los Angeles, California, United States
Contact: Study coordinator (Bartosz Chmielowski, MD)Stanford Cancer Institute, Palo Alto, California, United States
Contact: Study coordinator (Allison Betof Warner, MD)University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora, Colorado, United States
Contact: Study coordinator (Sapna Pradyuman Patel, MD)The Melanoma & Skin Cancer Institute, Englewood, Colorado, United States
Contact: Study coordinator (Ryan Weight, DO, MS)Georgetown University Medical Center, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Suthee Rapisuwon, MD)Mayo Clinic - Jacksonville FL, Jacksonville, Florida, United States
Contact: Study coordinator (Roxana S. Dronca, MD)Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Contact: Study coordinator (Leonel Fernando Hernandez Aya, MD)Emory Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Michael Lowe, MD)Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Study coordinator (Sunandana Chandra, MD, MS)University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Study coordinator (Daniel Olson, MD)University of Iowa, Iowa City, Iowa, United States
Contact: Study coordinator (Asad Javed, MD)Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Kamaneh Montazeri, MD)Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Arkadiusz Z. Dudek, MD)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Alexander Shoushtari, MD)Duke University Medical Center, Durham, North Carolina, United States
Contact: Study coordinator (April Salama, MD)The Ohio State University, Columbus, Ohio, United States
Contact: Study coordinator (Richard Wu, MD, PhD)Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Marlana Orloff, MD)UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Diwakar Davar, MD)The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States
Contact: Study coordinator (Arnel M. Pallera, MD)University of Tennessee Medical Center, Knoxville, Tennessee, United States
Contact: Study coordinator (Timothy Panella, MD)Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact: Study coordinator (Meredith Ann McKean, MD, MPH)Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville, Tennessee, United States
Contact: Study coordinator (Douglas B. Johnson, MD)UT Southwestern Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Sanjay Chandrasekaran, MD)The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Alexandra Ikeguchi, MD)Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Natalie Miller, MD, PhD)University Of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Contact: Study coordinator (Vincent Ma, MD)Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Contact: Study coordinator (Georgina Long, MD)Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact: Study coordinator (Damien Kee, MD)The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Merseyside, United Kingdom
Contact: Study coordinator (Joseph Sacco)The Royal Marsden NHS Foundation Trust, London, United Kingdom
Contact: Study coordinator (James Larkin)
Study leads
Rahul Marpadga, MD MPH
Study Director
Replimune, Inc.